PTGS2 and ovarian carcinoma: The OS of ovarian cancer patients prolonged with the high-expression of ATG7, G6PD, SLC3A2, MAP1LC3C and PTGS2, but shrank with the increased expression of NFS1, VDAC2, ACSL3 (Fig. 2a).